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Abstract
Hereditary erythermalgia is a painful and debilitating genetic disorder associated with mutations in
voltage-gated sodium channel Nav1.7. We have previously reported a Canadian family segregating
erythermalgia consistently with a dominant genetic etiology. Molecular analysis of the proband from
the family detected two different missense mutations in Nav1.7. In the present study we have
performed a long-term follow-up clinical study of disease progression in three affected family
members. A more extensive molecular study has also been completed, analyzing the segregation of
the two missense variants in the family. The two variants (P610T, L858F) segregate independently
with respect to clinical presentation. Detailed genotype/phenotype correlation suggests that one
of the two variants (L858F) is causal for erythermalgia. The second variant (P610T) may modify the
phenotype in the proband. This is the second reported study of potential compound heterozygosity
for coding polymorphisms in Nav1.7, the first being in a patient with paroxysmal extreme pain
disorder.
Findings
A Canadian family segregating erythermalgia as an appar-
ent dominant genetic trait was originally ascertained and
reported in 1979[1]. At the time, the female proband was
14 years old. She was reported to have two affected broth-
ers, however only the proband's condition was described.
She had already suffered double leg amputations at age
13, with regular severe episodes of pain and redness in the
extremities. A brief report of the family in 1987 noted that
the proband had suffered a near-fatal case of hypothermia
due to excessive use of a cooling apparatus to relieve pain-
ful symptoms[2]. One brother had suffered two leg ampu-
tations at age 20. The family was subsequently included in
a cohort of families used to map a locus for erythermalgia
to chromosome 2q31-32[3], and eventually molecular
analysis of the proband identified two missense variants
in voltage-gated sodium channel Nav1.7, amino acids
P610T and L858F[4]. Segregation of these two variants in
the remaining affected and unaffected family members
was not feasible at that time.
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We have now revisited the affected family members in a
long-term clinical follow-up (see Fig. 1).
Proband (III/3): The proband is a female now 43-years-
old. She has continued to suffer extremely debilitating
episodes of pain. On a scale of 1–10, with 10 the most
extreme, she reports her pain as 10 in the absence of mit-
igating treatments. She has had no further amputations
since the original ones at age 14. She reports burning, red-
ness and pain in hands, arms and legs (above the ampu-
tations) as well as eartips, but not her nosetip. She does
not suffer diarrhea. Symptoms are provoked by exercise or
warm temperatures or use of bed sheets, and are more
common during summertime. She is unable to wear
shoes, and unable to work. Symptoms are incompletely
alleviated by application of cold water or ice, air condi-
tioning, elevation of the painful extremity, or by treat-
ment with some medications.
Brother (III/1): The oldest brother is now age 49. He
reports having symptoms from birth, with burning and
reddened hands and ears. Both legs were partially ampu-
tated at age 20, he continues to experience symptoms in
the legs in the vicinity of the stumps. Symptoms are pro-
voked by heat or use of bed sheets and are alleviated by
application of ice or use of a ventilator. He does not wear
shoes and symptoms interfere with his ability to work or
leave the home. He does not use pain medication.
Brother (III/2): The second brother is now age 48. He
reports having symptoms from birth, with reddened and
burning painful hands, feet, and ears. He reports warm
and reddened but not painful nosetip. On a scale of 1–10
he reports pain at 8–9. He has suffered no amputations
but has discolored and ulcerated skin in the affected
regions. Symptoms are provoked by heat, exercise or use
of bed sheets, and increase during summertime. He
employs a ventilator but not ice or ice water for alleviation
of symptoms. He does not wear shoes. He has worked
sporadically and has experienced difficulties with adapt-
ing to inflexible work and school environments. Alcohol
use exacerbates symptoms.
Overall, although it is difficult to assess given the subjec-
tive nature of painful sensation, the proband appears to
experience significantly greater pain and discomfort than
her two siblings. This is based on the patients reports
according to a numeric rating scale, the need for stronger
medication and the requirement for amputations at a
young age. The development of a near fatal case of hypo-
thermia resulting from attempts to cool the extremities in
a search for relief is also suggestive of more severe pain.
Mother (II/1): The proband reports her mother was
affected with symptoms from childhood, but the mother
was unavailable for direct clinical examination.
In the original molecular study of this family the entire
coding region of Nav1.7 was sequenced in DNA from the
proband. Two missense mutations were reported, at
nucleotides C1828A and C2572T, corresponding to
amino acid changes P610T and L858F respectively. We
have now performed mutation analysis for these two var-
iants in all available family members, including the
affected mother, three affected and two unaffected sib-
lings (see Figure 1). The figure shows the segregation of
the two amino acid variants, as well as the microsatellite
haplotypes determined as part of the original fine map-
ping of the locus[3].
All three affected siblings and the affected mother carry
the L858F variant. Somewhat surprisingly however, the
second variant, P610T, is shared by the proband and the
unaffected but not the affected siblings. Microsatellite
haplotypes support the inference that the two variants are
in trans in the proband. Presumably the P610T variant was
transmitted from the unsampled father.
The L858F variant was independently reported in a Chi-
nese patient with erythermalgia[5]. L858 is located within
the DII/S4–S5 linker which is conserved among all mam-
Missense variants in Nav1.7 in erythermalgia family Figure 1
Missense variants in Nav1.7 in erythermalgia family. 
Canadian family with inherited primary erythermalgia. 
Colored bars represent derived haplotypes of the indicated 
microsatellite markers (haplos from deceased father are 
inferred). Segregation of two missense variants in Nav1.7, 
L858F (red star) and P610T (green star) are shown.Molecular Pain 2008, 4:21 http://www.molecularpain.com/content/4/1/21
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malian sodium channels, indicating a critical role in con-
trolling biophysical properties of these channels.
Interestingly, a different mutation at the same residue,
L858H, was found in a different Chinese family with ery-
thermalgia[6]. Electrophysiological studies document
that the L858F mutation affects the normal physiological
function of the channel and leads to increased hyperexita-
bility, as the mutant channel produces larger response to
only small stimuli[7]. The mutant channel also recovers
more quickly from inactivation. In addition, cooling
decreases the current density, slows deactivation and
increases ramp currents. This brings the function of the
channel within the range of the wild type protein.
Our findings are intriguing with respect to genotype/phe-
notype correlations of missense variants in Nav1.7. To a
first approximation, the disease in the family appears to
be caused by inheritance of the L858F mutation. This is
consistent with other genetic and functional studies of the
gene. Of itself P610T has no obviously demonstrable phe-
notype in carriers in our pedigree. P610 is located within
the cytosolic linker joining transmembrane segment S6 of
domain I and transmembrane segment S1 of domain II
and appears to be located within a conserved region of
SCN9a. However residues 609–611, though partly con-
served, are not invariant among vertebrate species (see
Table 1). Moreover, we found P610T in 10 out of 210 con-
trol Caucasian chromosomes. This further suggests that
P610T is not a highly penetrant pathogenic mutation. The
question remains whether P610T is able to modulate e.g.
exacerbate the phenotype of the proband carrying the
main causal variant, or to subtly influence sensitivity to
pain independently. This could arise through either of
two possibilities. First, P610T may be a very weak gain of
function (gof) allele of Nav1.7. Second, P610T may be a
loss of function (lof) allele. Human patients carrying loss
of function alleles of Nav1.7 suffer a rare genetic
hypoalgesia disorder called congenital indifference to
pain (CIP) [8-10]. However CIP is recessive, so that
affected patients are either homozygous or compound
heterozygous for two, normally nonsense, mutations in
the gene. Heterozygous carriers of Nav1.7 lof alleles have
normal pain thresholds, suggesting the absence of a
strong dose-sensitivity for Nav1.7. In the presence of a
presumptive hyperalgesic gof allele (such as L858F), the
occurrence of an lof allele in trans could potentially exac-
erbate the phenotype, due to the reduction in wild type
functional gene product. Our suggestion of functional
consequences of P610T is necessarily preliminary. A direct
test through in vitro electrophysiology is beyond the scope
of the present study. Such a test, complemented by popu-
lation based association tests of differential pain sensitiv-
ity, would be required to explore our hypotheses directly.
The genetics of Nav1.7 provides substantial complexities.
Broadly, mutations in the gene lead to one of three differ-
ent phenotypes[11,12]. As noted, lof alleles lead to reces-
sive hypoalgesia. A class of aberrant, or gof mutations,
confirmed in many cases by electrophysiological studies,
cause erythermalgia[4-7,13-24]. A third class of alleles
cause another hyperalgesia condition, known originally
as familial rectal pain and now as paroxysmal extreme
pain disorder (PEPD) [25-27]. PEPD alleles of Nav1.7 are
likewise missense variants, suggesting that they also have
aberrant function (gof). They cause spontaneous rectal,
ocular or submandibular pain with reddening. The rea-
sons for the different tissue distribution of the symptoms
of erythermalgia and PEPD remain to be determined. The
causal alleles for each condition are distributed across var-
ious regions of the gene (see Figure 1 of Drenth and Wax-
man[12]), although most mutant PEPD alleles are further
C-terminal than most erythermalgia alleles. Expression
and further electrophysiological studies have partly clari-
fied this issue, with subtle differences in in vitro biophysi-
cal effects of PEPD versus erythermalgia mutant alleles.
One likely case of compound heterozygosity for two mis-
sense Nav1.7 alleles was reported in a PEPD patient[25],
making this the second report of a potential compound
heterozygote for two mutant alleles in this gene.
A challenge with interpretation of the case literature on
treatment of these diseases is the occurrence of non-genetic
disorders with very similar presentation (i.e. phenocopies).
Particularly in the case of erythermalgia, there is an exten-
sive literature on other causes of the condition, although in
most cases a potential genetic etiology was probably not
explored or even discussed[28]. So far, genetic analyses of
familial and sporadic cases have been mostly restricted to
cases with known childhood onset, on the presumption
that adult onset is more likely to be caused by other non-
genetic factors. This remains an assumption however, and
will require further molecular genetic study. There are
clearly many additional questions to answer about the role
of Nav1.7 in sporadic and provoked pain sensation.
Table 1: The P610T SCN9A mutation detected in this study is in 
bold, and for comparison the corresponding amino acids from 
various species are included. Note that PPM residues 609–611 
are highly but not totally conserved among mammalian species.
Homo sapiens NISQASRSPPMLPVNGKMHSA
Macaca mulatta NISQASRSPPILPVNGKMHSA
Equus caballus NISQASRSPPMLPVNGKMHSA
Bos taurus NISQASRSPPVLPVNGKMHSA
Canis familiaris NISQASRSPPVLPVNGKMHSA
Rattus norvegicus NISQASRSPPVLPVNGKMHSA
Mus musculus NISQASRSPPVLPVNGKMHSA
Cavia porcellus NISQASRSPPMLPVNGKMHSA
Dasypus novemcinctus NISQASRSPPMLPVNGKMHSA
Monodelphis domestica NISQASRSPRMLPVNGKMHSA
Ornithorhyncus anatinus NLSQASRSLRMLPVNGKMHST
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